

## Abbott's Acquisition of Alere at a Glance

### TODAY'S ANNOUNCEMENT

Abbott has agreed to acquire Alere (NYSE: ALR), the Massachusetts-based point of care testing company, significantly advancing its diagnostics presence and leadership. Abbott's total diagnostics sales will exceed \$7 billion after the close.

### FINANCIAL

- Abbott will pay \$56 per common share at a total expected equity value of \$5.8 billion
- Immediately accretive to Abbott's ongoing EPS upon close and significantly accretive thereafter, with approximately 12-13 cents of accretion in 2017 and more than 20 cents in 2018\*
- Anticipated to result in annual pre-tax synergies approaching \$500 million by 2019 and increasing thereafter, including both sales and operational benefits
- Alere's net debt, currently \$2.6 billion, will be assumed or refinanced by Abbott

### ALERE

- Leader in point of care diagnostics with annual sales of \$2.5 billion
- Headquartered in Waltham, Mass., with 9,800 employees worldwide
- Broad menu of infectious disease, molecular, cardiometabolic and toxicology tests
- Delivered more than 1.4 billion tests at the point of care in 2015
- Developed first-ever CLIA-waived molecular test for flu and strep that delivers results in under 15 minutes

### ABBOTT'S DIAGNOSTICS BUSINESS

- Annual revenue of \$4.6 billion with point of care comprising \$473 million in 2015
- Broad portfolio spanning immunoassay, clinical chemistry, hematology, blood screening, molecular and point of care
- Abbott's i-STAT<sup>®</sup> handheld analyzer is a portable, handheld device to analyze blood test results at a patient's side within minutes
- i-STAT measures 26 different analytes or substances in the body, including cardiac, blood gases, chemistries/electrolytes, coagulation, lactate and hematology
- More than 75,000+ i-STAT analyzers used worldwide

*\*Ongoing earnings per share excludes specified items such as amortization of acquired intangibles, inventory step-up, restructuring costs and other costs incurred to execute the transaction. Ongoing EPS is a non-GAAP financial measure and should not be considered a replacement for GAAP results.*

